Responses
Oral Abstracts
Opening Ceremony and Plenary 1: Oral Abstract Presentations
O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.